Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,232,279
  • Shares Outstanding, K 322,916
  • Annual Sales, $ 229,210 K
  • Annual Income, $ -116,450 K
  • 60-Month Beta 1.29
  • Price/Sales 28.64
  • Price/Cash Flow N/A
  • Price/Book 50.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.15
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.07 +10.49%
on 02/21/19
23.25 -18.88%
on 03/05/19
+1.32 (+7.53%)
since 02/19/19
3-Month
11.78 +60.10%
on 12/24/18
23.25 -18.88%
on 03/05/19
+3.84 (+25.57%)
since 12/19/18
52-Week
2.35 +702.55%
on 07/31/18
23.33 -19.16%
on 11/06/18
+15.60 (+478.53%)
since 03/19/18

Most Recent Stories

More News
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VALE, SVXY, AMRN and NIO

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

SVXY : 53.00 (-0.45%)
NIO : 5.96 (+3.65%)
AMRN : 18.86 (-2.28%)
VALE : 13.70 (+3.16%)
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Amarin Corporation To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation ("Amarin" or the "Company")(NASDAQ:AMRN) of the April 23, 2019 deadline to seek the role of lead plaintiff...

AMRN : 18.86 (-2.28%)
CLASS ACTION UPDATE for AMRN, CNDT, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

CRBP : 7.47 (+8.73%)
CNDT : 13.99 (-1.55%)
NIO : 5.96 (+3.65%)
AMRN : 18.86 (-2.28%)
Clinical Trials for Leukemia Exhibiting Encouraging Advancements

Recent developments mentioned in industry sourced article from Medicalexpress.com, a research and technology news service, it was encouraging to see an optimistic headline in cancer treatments. One article...

AMRN : 18.86 (-2.28%)
MRK : 81.91 (+0.69%)
MBRX : 1.27 (+1.60%)
DARE : 1.80 (-14.29%)
PHAS : 6.20 (-0.48%)
HLS Therapeutics Announces Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Amarin Corporation plc (NASDAQ:AMRN),...

AMRN : 18.86 (-2.28%)
HLS.TO : 15.40 (+2.67%)
HLS Therapeutics Announces High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Atherosclerotic Cardiovascular Disease

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that on March 16, 2019, Amarin Corporation...

AMRN : 18.86 (-2.28%)
HLS.TO : 15.40 (+2.67%)
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology's 68th Annual Scientific Session

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, in addition to its previously announced data from scientific presentations at the American College...

AMRN : 18.86 (-2.28%)
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Levels

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that real-world data reported by the U.S. Veteran's Administration supports that...

AMRN : 18.86 (-2.28%)
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT(TM)

Amarin Corporation plc (NASDAQ: AMRN), presented new data from its landmark cardiovascular outcomes study of its prescription therapy, Vascepa® (icosapent ethyl), the REDUCE-IT(TM) study, showing that...

AMRN : 18.86 (-2.28%)
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DBVT, AMRN, WTW and CRBP

The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies...

CRBP : 7.47 (+8.73%)
DBVT : 8.47 (+3.55%)
AMRN : 18.86 (-2.28%)
WTW : 19.84 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade AMRN with:

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

2nd Resistance Point 20.29
1st Resistance Point 19.57
Last Price 18.86
1st Support Level 18.45
2nd Support Level 18.05

See More

52-Week High 23.33
Last Price 18.86
Fibonacci 61.8% 15.32
Fibonacci 50% 12.84
Fibonacci 38.2% 10.36
52-Week Low 2.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar